Financial Sector Declines 0.7%, JPMorgan Down 3.8%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 13 2026
0mins
Should l Buy DVA?
Source: NASDAQ.COM
- Financial Sector Decline: As of midday Tuesday, the financial sector is down 0.7%, with JPMorgan Chase (JPM) and Progressive Corp (PGR) showing losses of 3.8% and 3.6%, respectively, indicating a weakening trend that may affect investor confidence.
- Poor ETF Performance: The Financial Select Sector SPDR ETF (XLF) is down 1.7% on the day and 0.73% year-to-date, reflecting the overall malaise in the financial market, which could lead to capital outflows from the sector.
- Healthcare Sector Follows: The healthcare sector is down 0.5%, with Solventum Corp (SOLV) and DaVita Inc (DVA) experiencing declines of 5.2% and 4.2%, respectively, indicating pressure in the healthcare industry that may influence investor decisions.
- Healthcare ETF Tracking: The Health Care Select Sector SPDR ETF (XLV) is down 0.6% on the day, although it is up 1.06% year-to-date, but the poor performance of SOLV and DVA may impact the ETF's attractiveness.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DVA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DVA
Wall Street analysts forecast DVA stock price to rise
5 Analyst Rating
1 Buy
3 Hold
1 Sell
Hold
Current: 147.750
Low
144.00
Averages
162.50
High
190.00
Current: 147.750
Low
144.00
Averages
162.50
High
190.00
About DVA
DaVita Inc. is a healthcare provider focused on transforming care delivery to improve the quality of life for patients globally. The Company is a provider of kidney care services in the United States. Its United States dialysis (U.S. dialysis) and related lab services business treats patients with chronic kidney failure and end-stage kidney disease (ESKD). The Company’s robust platform delivers kidney care services and includes established nephrology and payor relationships. The Company’s international operations provide dialysis and administrative services to a total of outpatient dialysis centers. The Company’s U.S. integrated kidney care (IKC) business provides integrated care and disease management services to patients in risk-based integrated care arrangements and to additional patients in other integrated care arrangements across the United States. It also maintains a few other ancillary services and investments outside its U.S. dialysis, U.S. IKC, or international operations.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

- Buffett's Departure: On December 31, 2025, Warren Buffett stepped down as CEO of Berkshire Hathaway after 60 years of leadership, yet the company remains stable as successors continue his investment strategies without major changes to the portfolio initiated during his tenure.
- Chubb Investment Outlook: Berkshire currently holds an 8.8% stake in Chubb valued at approximately $11.2 billion, and while an acquisition remains uncertain, Chubb anticipates double-digit growth in earnings per share and tangible book value for 2026, indicating strong financial performance and ongoing dividend growth potential.
- Chevron Growth Drivers: Chevron's stock has surged 20% since the beginning of the year, and despite a current P/E ratio of 24, akin to tech stocks, the company has made significant progress in exploration contracts in Libya, Syria, and Turkey, which are expected to drive future earnings growth and stock price appreciation.
- DaVita Recovery Signs: Berkshire has held shares in DaVita since 2011, and despite the stock trading sideways for much of the decade, it has rallied 32% since early 2026, with management projecting a 25% to 39% increase in adjusted earnings per share for 2026, reflecting growth potential from international expansion, although Berkshire recently reduced its stake to maintain ownership below 45%.
See More
Berkshire Hathaway Stock Sale: Berkshire Hathaway sold approximately $27 million worth of Liberty Live Group stock in January.
Investment Manager's Holdings: Berkshire investment manager Ted Weschler and his family own around $22 million in Liberty Live Group stock.
See More
- New Investment Disclosure: Berkshire Hathaway disclosed a new position of 5,065,744 shares in The New York Times Co (NYSE:NYT) for Q4 2025, indicating a sustained interest in the media sector.
- Liberty Media Ecosystem Adjustment: In its 13F filing, Berkshire clarified its holdings within the restructured Liberty Media ecosystem, including 3,018,555 shares of Liberty Formula One (NASDAQ:FWONK), reflecting confidence in the racing business.
- Portfolio Changes Overview: The Q4 13F report revealed changes in Berkshire's existing stock holdings, particularly notable reductions in certain stocks, indicating a dynamic adjustment in its investment strategy.
- Apple Holdings Dynamics: Although Berkshire reduced its stake in Apple once again, it remains the largest position in its investment portfolio, demonstrating a long-term bullish outlook on the technology sector.
See More

- Berkshire Hathaway's Investment Changes: The company reduced its holdings in Bank of America and Apple during the fourth quarter.
- New Investment in New York Times: Berkshire Hathaway initiated a new position by purchasing five million shares of the New York Times.
- Regulatory Filing: These changes were disclosed in a 13-F filing after the close of trading on Tuesday.
- Market Impact: The adjustments in investment strategy reflect Berkshire Hathaway's ongoing portfolio management and market positioning.
See More
- Buffett's Leadership Achievements: Buffett served as CEO of Berkshire Hathaway from 1965, achieving an average annual stock price increase of about 20%, significantly outperforming the S&P 500's 10.3%, highlighting the success and sustainability of his investment strategies.
- Signs of DaVita's Recovery: DaVita exceeded expectations in its latest quarterly results and provided 2026 earnings guidance between $13.60 and $15, with shares surging over 30% since the earnings release, indicating restored market confidence and future growth potential.
- Investment Opportunity in Kraft Heinz: Despite Berkshire's losses in Kraft Heinz, the current market cap of around $7.5 billion and a forward P/E of 9 attract new investors, especially as the company plans to split to unlock value, reminiscent of Kellogg's successful separation strategy.
- Cautious Stance on UnitedHealth Group: Although Berkshire purchased 5 million shares last year, the stock has fallen from $350 to around $280 due to lower-than-expected Medicare payment increases, prompting investors to think twice before buying the dip given the potential for further multiple compression.
See More
- Strong Earnings Performance: DaVita's latest quarterly results exceeded expectations, with projected earnings per share between $13.60 and $15 for 2026, resulting in a current price-to-earnings ratio of only 9 times, indicating potential for future growth and attracting investor interest.
- Stock Price Rebound: Since the earnings release, DaVita's stock has surged over 30%, reflecting market recognition of its performance and potentially providing room for multiple expansion, as it previously traded at 13 to 14 times forward earnings.
- Buffett's Investment Strategy: Despite Berkshire Hathaway's losses on its Kraft Heinz investment, currently valued at around $7.5 billion, the planned split into two entities may present opportunities for new investors, especially as Kraft Heinz trades at a mere 9 times forward earnings, below peers.
- Healthcare Sector Challenges: UnitedHealth Group's stock has fallen from $350 to around $280, primarily due to the U.S. government's lower-than-expected Medicare payment increases; although Buffett had previously purchased shares, the current 16 times forward earnings ratio indicates market concerns about its growth trajectory, warranting caution for investors.
See More









